This phase II trial is evaluating the effectiveness and safety of chemotherapy (Mfolfirinox) and stereotactic radiotherapy in people with locally advanced pancreatic cancer.
This trial is treating patients with pancreatic cancer.
This is a radiation therapy, systemic therapy and surgical trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
Australasian Gastro-Intestinal Trials Group (AGITG)
Eligible participants will be randomised on a 2:1 basis based on minimisation and stratification by tumour stage, planned chemotherapy and institution, to one of two arms. Participants in the Experimental Arm will receive chemotherapy (12 week of mFOLFIRINOX and/or 12 additional weeks of gemcitabine/capecitabine), followed by radiation therapy (SBRT) to commence within 3 weeks of completing initial chemotherapy (40 Gray [GY] in 5 fractions over 2 weeks). Eligible participants will receive surgery 6 weeks post-completion of initial surgery. Patients who are not eligible for surgery will continue ongoing chemotherapy.
Participants in the Active Comparator Arm will receive chemotherapy (12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine). Eligible participants will receive surgery 6 weeks post-completion of initial surgery. Patients who are not eligible for surgery will continue ongoing chemotherapy.
Recruiting Hospitals Read More